GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karyopharm Therapeutics Inc (FRA:25K) » Definitions » Shiller PE Ratio

Karyopharm Therapeutics (FRA:25K) Shiller PE Ratio : (As of Jun. 23, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Karyopharm Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Karyopharm Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Karyopharm Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karyopharm Therapeutics Shiller PE Ratio Chart

Karyopharm Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Karyopharm Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Karyopharm Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Karyopharm Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Karyopharm Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Karyopharm Therapeutics's Shiller PE Ratio falls into.



Karyopharm Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Karyopharm Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Karyopharm Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.294/131.7762*131.7762
=-0.294

Current CPI (Mar. 2024) = 131.7762.

Karyopharm Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -0.405 100.560 -0.531
201409 -0.473 100.428 -0.621
201412 -0.641 99.070 -0.853
201503 -0.684 99.621 -0.905
201506 -0.820 100.684 -1.073
201509 -0.757 100.392 -0.994
201512 -0.744 99.792 -0.982
201603 -0.674 100.470 -0.884
201606 -0.748 101.688 -0.969
201609 -0.615 101.861 -0.796
201612 -0.616 101.863 -0.797
201703 -0.664 102.862 -0.851
201706 -0.570 103.349 -0.727
201709 -0.545 104.136 -0.690
201712 -0.676 104.011 -0.856
201803 -0.633 105.290 -0.792
201806 -0.514 106.317 -0.637
201809 -0.677 106.507 -0.838
201812 -0.844 105.998 -1.049
201903 -0.965 107.251 -1.186
201906 -0.628 108.070 -0.766
201909 -0.608 108.329 -0.740
201912 -0.684 108.420 -0.831
202003 -0.706 108.902 -0.854
202006 -0.559 108.767 -0.677
202009 -0.620 109.815 -0.744
202012 -0.485 109.897 -0.582
202103 -0.647 111.754 -0.763
202106 -0.589 114.631 -0.677
202109 -0.587 115.734 -0.668
202112 0.407 117.630 0.456
202203 -0.481 121.301 -0.523
202206 -0.587 125.017 -0.619
202209 -0.455 125.227 -0.479
202212 -0.406 125.222 -0.427
202303 -0.280 127.348 -0.290
202306 -0.268 128.729 -0.274
202309 -0.281 129.860 -0.285
202312 -0.330 129.419 -0.336
202403 -0.294 131.776 -0.294

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Karyopharm Therapeutics  (FRA:25K) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Karyopharm Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Karyopharm Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Karyopharm Therapeutics (FRA:25K) Business Description

Traded in Other Exchanges
Address
85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.

Karyopharm Therapeutics (FRA:25K) Headlines

No Headlines